ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2051

The Lasso Selection Model in Rheumatology Epidemiologic Studies

Sofia Pedro1, Bella Mehta2, Gulsen Ozen3,4 and Kaleb Michaud1,5, 1National Data Bank for Rheumatic Diseases, Wichita, KS, 2Rheumatology, Hospital of Special Surgery, New York, NY, 3Rheumatology, Marmara University, School of Medicine, Rheumatology, Istanbul, Turkey, 4Department of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5University of Nebraska Medical Center, Omaha, NE

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Statistical methods

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: ARHP Measures and Measurement of Healthcare Quality Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Selecting the best model in an epidemiologic analysis is challenging as it addresses problems like confounding and allows the estimation of unbiased results. Stepwise selection is the most commonly used method but also the most criticized, as it relies on an arbitrary threshold, the probability of removal, to decide which variables will be included in the model. Modern shrinkage techniques such as the Least Absolute Shrinkage and Selection Operator (LASSO) may address this issue. Using a rheumatology patient registry, we compared the LASSO method with traditional regression model techniques including stepwise and change-in-estimate.

Methods:

LASSO can be used with several statistical models including generalized linear models and proportional hazards models. In the latter, it maximizes the partial likelihood of regression coefficients subject to a constraint imposed on the sum of the absolute value of all regression coefficients. It excludes variables without formal statistical testing by correcting the extremes in the distribution and shrinking unstable estimates to zero. The constraint can be estimated via cross-validation. We illustrate this technique in a sample of patients enrolled in the National Data Bank for Rheumatic Diseases from 2001 to 2016. We applied survival methods to assess the risk of serious infections (SI) in patients with RA compared to non-inflammatory rheumatic disease (NIRD) controls. Variables included demographics, clinical status, disease severity and prednisone use.

Results:  

20,361 RA and 6176 NIRD patients contributed to 81,499 and 20,665 patient-years of exposure, having had 1600 (7.9%) and 276 (4.5%) SI, respectively (incidence rate ratio: 1.5 [1.3-1.7]). Baseline characteristics by disease (RA:NIRD) were age (58:63 yrs), female sex (79:80%) and HAQ (1.11: 1.10). The LASSO HR of SI comparing RA vs NIRD was 1.15 (0.99 – 1.32), being prednisone, vaccination, and prior infections the variables with the highest impact (Figure). Similar results were obtained with stepwise, selecting almost the same covariates. However, when using different thresholds, slightly different models were obtained (Table).

Conclusion:

Identical estimates were obtained across methods, not imposing arbitrary thresholds with LASSO. Although LASSO has many positive attributes, such as being very powerful when variables exceed observations, it is still rarely applied in epidemiologic studies. It is a valid alternative to the popular stepwise, as it is less variable and yields interpretable models.

Table. Best Cox models selected for serious infections accordingly to several selection techniques.

Method

HR (RA vs NIRD)

Other variables selected

LASSO

1.15 (0.99-1.32)

Ethnicity (white vs. other), sex, smoking status, age, disease duration, residency (urban vs. rural), prior infections, RD comorbidity index, HAQ, pain, education, prednisone, vaccination, diabetes

Change-in-estimate

 (10% change)

1.13 (0.98-1.30)

Prednisone

Change-in-estimate

 (2% change)

1.17 (1.01-1.34)

Prednisone, pain, age, education

Stepwise

 (20% removal probability)

1.14 (1.0-1.31)

Ethnicity (white vs. other), sex, smoking status, age, disease duration, residency (urban vs. rural), prior infections, RD comorbidity index, HAQ, pain, education, prednisone, vaccination, diabetes

Stepwise

(10% removal probability)

1.15 (1.0-1.32)

Ethnicity (white vs. other), sex, smoking status, age, disease duration, prior infections, RD comorbidity index, HAQ, pain, education, prednisone, vaccination, diabetes

 

Figure. LASSO coefficients estimates by the regularization term.


Disclosure: S. Pedro, National Data Bank for Rheumatic Diseases, 3; B. Mehta, None; G. Ozen, None; K. Michaud, None.

To cite this abstract in AMA style:

Pedro S, Mehta B, Ozen G, Michaud K. The Lasso Selection Model in Rheumatology Epidemiologic Studies [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/the-lasso-selection-model-in-rheumatology-epidemiologic-studies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-lasso-selection-model-in-rheumatology-epidemiologic-studies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology